Viaderma Inc (OTCMKTS:VDRM) Moves to Phase II Testing on Cannabis Tech

1240

The last time we touched upon Viaderma Inc (OTCMKTS:VDRM) was earlier this spring, when the stock had shot up over 800% after it received provisional patent numbers for FDA-registered Viabecline and Cannabis Technologies.

This week, we wanted to circle back around to VDRM after the company reported positive results from Phase I testing on those technologies, as well as the commencement of Phase II testing.

Viaderma Inc (OTCMKTS:VDRM) aims at developing an approved method for delivering medical and recreational cannabinoids to the body. The testing was performed in British Columbia, Canada with THC and has proven very successful.

The Company plans to conduct medical research and clinical trials to develop Cannabinoids-based pharmaceuticals and treatments for conditions including, but not limited to, psoriasis, fibromyalgia, PTSD, Depression, Anxiety and migraines. The Company will also be pursuing the “Recreational Market” in Canada with expansion plans into the USA once the proper legal standards are addressed.

“THC, CBD, and CDN are more commonly known Cannabinoids found in the Cannabis and Hemp plants but there are over 100 known Cannabinoids that our technology can be used for. As pharmaceutical companies develop different cannabinoids for treating various medical conditions our delivery system, we believe, will be the premiere way of dosing and delivering the medication transdermally,” said CEO Dr. Chris Otiko.

ViaDerma will be begin developing unique delivery systems for the effective delivery and dosage of recreational and medical cannabinoids and plans to start a grass roots product for both THC and non-THC Cannabinoids, both in a patch form, roll on and spray. The plans include distribution in every dispensary across Canada to start with, and add a website for global distribution.

 

The Company’s success of its first round of testing is compelling and the company plans to start continued Clinical Trials to ensure that the delivery system meets medical standards. The idea is to continue and expand testing to include pure Cannabinoid isolates, including pure THC oil, to ensure that developed products will be accepted by the medical community to treat illness as well as providing the recreational market with a more favorable alternative to smoking or ingesting.

Otiko said, “We are very excited our initial tests absorbed THC into the body using our proprietary patent pending delivery system for Cannabinoids by applying the medication onto the skin in an ointment based topical solution. Plans are, in addition to our own products, eventually license the technology to global Pharmaceutical Licensed Producers of Cannabinoids

 

for their medical and recreational products as well as smaller companies that produce the Home-Grown Hand Crafted Strains of medical and recreational products.”

Earlier this year the Company signed a Licensing Agreement with a Canadian group with expertise in logistics and development that includes distribution for the new and anticipated products. The Management Company is developing the trial protocols, products, and eventually the sales for the new patent pending products to countries that have accepted “Medical Marijuana” and “Recreational Use” of cannabis products and technologies for the delivery of Cannabinoids. The management company will also target countries that allow the “Clinical Studies” for medical testing such as the United Kingdom and other Asian countries. (Source: Marketwired)

We like VDRM’s approach to the recreational market in Canada, which is certainly further along in the march toward full legalization than its American counterpart. While the US is dealing with an administration that has all but reversed that momentum, Canada plans to move ahead with nationwide legalization in 2018. It’s one more aspect that draws us to continue to keep an eye on VDRM. Stay locked to Street Register for updates, and we’ll deliver important developments on VDRM as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in VDRM stock, short or long.

LEAVE A REPLY